Cindy L Chepanoske

US Patent:

20090214465, Aug 27, 2009

Filed:

Jan 25, 2006

Appl. No.:

11/883092

Inventors:

Robert R. Becklin - Layton UT, US
Cindy Lou Chepanoske - Salt Lake City UT, US
John M. Peltier - Jefferson MD, US
Longwu Qi - West Lafayette IN, US
Paul B. Robbins - Park City UT, US
Sudhir R. Sahasrabudhe - Sandy UT, US
Robert Selliah - Midvale UT, US
Keith Simmon - West Valley City UT, US
Brent R. Stockwell - New York NY, US
Raj Gopal Venkat - Salt Lake City UT, US
Moritz von Rechenberg - Waltham MA, US
Eugene Y. Zhen - Carmel IN, US

Assignee:

PROLEXYS PHARMACEUTICALS, INC. - Salt Lake City UT
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH - Cambridge MA
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF - New York NY

International Classification:

A61K 38/20
A61K 31/496
A61K 38/21
A61K 39/395
C12N 5/00
C07D 239/72
C12Q 1/68
C12Q 1/02
G01N 33/53
A61K 38/16
A61K 31/7052
C07D 243/08
C07D 403/02
A61K 31/551
A61K 31/55
A61P 35/00

US Classification:

424 852, 51425217, 424 854, 4241331, 435375, 544287, 435 6, 435 29, 435 72, 514 12, 514 44 R, 540575, 540600, 514218, 51421706

Abstract:

The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.